Immune checkpoint inhibitors (ICIs) are a major class of immuno-oncology therapeutics that
have significantly improved the prognosis of various cancers, both in (neo) adjuvant and …

Aims The risk and incidence of cardiovascular (CV) immune-related adverse events (irAEs)
associated with immune checkpoint inhibitors (ICIs) in cancer patients remain unknown …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

Expanding the US Food and Drug Administration–approved indications for immune
checkpoint inhibitors in patients with cancer has resulted in therapeutic success and …

Background: Immune checkpoint inhibitors (ICIs) are monoclonal antibodies used to activate
the immune system against tumor cells. Despite therapeutic benefits, ICIs have the potential …

Simple Summary This review article addresses the toxic effects on the heart associated with
the use of certain cancer-treating drugs known as immune checkpoint inhibitors. These …

Over the last decade or so, there has been a paradigm shift in the oncologic care of patients
with a range of solid tumour and haematologic malignancies, away from traditional cytotoxic …

In both cardiovascular disease and cancer, there are established sex-based differences in
prevalence and outcomes. Males and females may also differ in terms of risk of cardiotoxicity …

As the clinical applications of immune checkpoint inhibitors (ICIs) expand, our knowledge of
the potential adverse effects of these drugs continues to broaden. Emerging evidence …

Background Immune checkpoint inhibitors (ICIs) have significantly changed the oncology
clinic in recent years, improving survival expectations in cancer patients. ICI therapy have a …